Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc., trading under the ticker BLUW, filed an 8-K current report with the Securities and Exchange Commission on September 6, 2022 (accession number 0001213900-22-054293). BLUW is a special purpose acquisition company operating in the pharmaceutical and life sciences sector, with a strategic focus on therapeutics businesses. The September 2022 current report represents a material disclosure event within the company's SPAC lifecycle, whether tied to a business combination update, corporate development, or other triggering event. For the full filing history, sponsor details, deal timeline, and comparable transaction data on BLUW, sign up for complete access on SpacDesk.